You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Angelini Pharma acquires CNS specialist Arvelle Therapeutics

Angelini Pharma has acquired Swiss biopharmaceutical company Arvelle Therapeutics for a total consideration of up to $960m.